Soleno Therapeutics Inc (SLNO) Stock Analysis and Metrics

Soleno Therapeutics

NASDAQ: SLNO

$53.01 ▲ +0.00 (+0.00%)

At close: May 18, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap874.25 Mn

P/E-14.91

P/S3.07

Div. Yield0.00

Total Debt (Qtr)49.87 Mn

Add ratio to table…

About

Soleno Therapeutics Inc is a biopharmaceutical company focused on developing novel therapeutics for rare diseases. Its lead product candidate, VYKAT XR (diazoxide choline) extended release tablets, received approval from the U. S. Food and Drug Administration on March 26, 2025 for the treatment of hyperphagia in adults and pediatric patients aged 4 years and older with Prader Will syndrome. VYKAT XR contains diazoxide choline, a potent ATP sensitive potassium channel activator that modulates neuronal and metabolic pathways implicated in appetite regulation. The company is headquartered in Redwood City, California and operates in the biopharmaceutical industry. Soleno Therapeutics aims to address the significant unmet medical need for effective therapies that reduce excessive food intake and improve behavioral outcomes in Prader Will syndrome patients. Beyond PWS, the company’s patent portfolio includes compositions and methods relevant to Smith-Magenis syndrome, suggesting potential future expansion of its therapeutic pipeline. Soleno Therapeutics continues to invest in research and development to identify additional rare disease indications where its K ATP modulator platform may provide clinical benefit.

We generate revenue primarily from the sale of VYKAT XR, which is priced on a weight based basis at $6.0976 per milligram. The product is distributed through a specialty pharmacy network that dispenses the medication upon receipt of a prescription from a qualified healthcare provider. Initial shipments to patients began in April 2025 and the company started recognizing revenue from VYKAT XR sales during the quarter ended June 30, 2025. In addition to direct product sales, Soleno Therapeutics offers patient support programs through its SOLENO ONE platform that provide education, counseling and financial assistance where applicable. These support initiatives do not constitute a separate revenue stream but are designed to improve access and adherence to the prescribed therapy. Manufacturing of VYKAT XR is outsourced to third party contract manufacturing organizations that handle active pharmaceutical ingredient production, drug product formulation, packaging and distribution under strict quality and regulatory oversight.

Soleno Therapeutics occupies a pioneering position as the first company to secure FDA approval for a treatment targeting hyperphagia in Prader Will syndrome patients. While growth hormone products are approved for growth failure in PWS, they do not affect appetite control, leaving a clear unmet need that VYKAT XR fulfills. The orphan drug designation granted to VYKAT XR provides up to 7 years of market exclusivity in the United States for the approved indication. Market research estimates that approximately 300,000 to 400,000 individuals worldwide live with Prader Will syndrome. Based on analyses of claims data, Soleno Therapeutics has identified roughly 10,000 individuals who have received a PWS specific treatment or carried a PWS related ICD10 code in 2022 or 2023. Several biotechnology firms, including Aardvark Therapeutics, Bright Minds Biosciences, Consynance, Harmony Biosciences, Neuren Pharmaceuticals, OT4B, Palobiofarma and Rhythm Pharmaceuticals, have drug candidates in various stages of development for PWS related hyperphagia and behavioral symptoms. The company’s competitive advantages stem from the novel mechanism of diazoxide choline as a K ATP channel activator, its extended release formulation enabling once daily dosing, and the potential to improve multiple disease manifestations such as insulin resistance and body composition. Soleno Therapeutics also benefits from a focused commercial organization of approximately 65 field personnel, including rare disease specialists and clinical nurse educators, which supports targeted outreach to prescribing physicians and treatment centers. The combination of regulatory exclusivity, differentiated pharmacology and a dedicated sales force positions the company to capture a meaningful share of the diagnosed PWS population in the United States.

The company serves patients diagnosed with Prader Will syndrome, a rare genetic disorder affecting both genders and occurring in approximately 1 in every 15,000 live births. These patients are typically managed by multidisciplinary care teams led by pediatric or adult endocrinologists and often receive care at specialized clinics, university affiliated hospitals or residential group home settings. Treatment is initiated following a prescription from a qualified healthcare provider and the medication is dispensed through specialty pharmacy channels that handle prior authorization and delivery to the patient’s home or care facility. Caregivers and family members play an important role in monitoring adherence and supporting lifestyle adjustments that complement the pharmacological intervention. No specific customer names are disclosed in the filing, but the target population includes both pediatric and adult individuals living with Prader Will syndrome. The company’s commercial organization engages with prescribing physicians, pharmacists and care coordinators to ensure appropriate use of VYKAT XR within the prescribed treatment paradigm.

Investment Thesis

▲ Bull case

Soleno Therapeutics, Inc. is positioned for significant upside from the near-term approval and commercial launch of VICAT XR in the European Union, an opportunity management highlighted but did not fully quantify in terms of near-term revenue impact. The company has already navigated the Day 120 questions from the EMA and is anticipating Day 180 questions imminently, with a decision expected in mid-year 2026. Given the concentrated nature of the PWS patient population in Europe—estimated at 9,500 individuals under E4—and the strong presence of centers of excellence and thought leader support, the path to adoption could mirror or exceed the U.S. launch trajectory. Management noted they are building their own commercial team on the ground, indicating confidence in a standalone launch capability, which would preserve full economic value. The U.S. launch achieved approximately 12.5% penetration of the addressable market in under nine months, translating to 859 active patients by year-end 2025. Applying a similar adoption rate in the EU could yield over 1,100 patients within the first year post-approval, generating substantial incremental revenue at current U.S. pricing levels. This expansion represents a structural growth catalyst that the market may be underestimating, particularly as the company transitions from a single-geography to a dual-commercial entity, derisking its revenue base and enhancing long-term scalability.
The ongoing development of VICAT XR for glycogen storage disease type 1 (GSD1) presents a high-probability, low-cost pipeline catalyst that could significantly extend the drug’s commercial lifespan and address a clear unmet need with minimal commercial overlap. Management explicitly identified GSD1 as a natural extension of the VICAT XR franchise, noting the shared physician base (pediatric endocrinologists), the mechanism of action’s direct applicability to hypoglycemia prevention, and the orphan designation already secured in both the U.S. and EU. The company plans to file an IND in 2026, leveraging existing knowledge of the drug’s pharmacology and safety profile. Unlike de novo drug development, this indication benefits from prior clinical exposure, reducing both development risk and time-to-trial initiation. With approximately 3,000–4,000 patients in the U.S. and a similar prevalence globally, GSD1 represents a meaningful secondary market that could be commercialized with a lean, focused effort—potentially through the same specialty pharmacy and field infrastructure already in place for PWS. The lack of existing FDA-approved therapies and the life-threatening nature of untreated GSD1 create strong pricing and reimbursement potential, while the drug’s ability to reduce dependence on frequent cornstarch dosing offers a compelling quality-of-life benefit that could drive rapid adoption among neurologists and metabolic specialists. This pipeline expansion is not being promoted as a near-term revenue driver but could become a material contributor to growth by 2028–2029, offering optionality that the market is not currently pricing in.
Soleno Therapeutics, Inc. exhibits signs of durable pricing power and reimbursement resilience that could support margin expansion and sustained revenue growth beyond initial launch dynamics, a factor that received limited emphasis during the earnings call despite strong underlying evidence. The company reported broad commercial, Medicaid, and Medicare coverage policies covering over 180 million lives by the end of 2025, including strong reimbursement from approximately 45 state Medicaid programs. Payers are recognizing the serious unmet need in treating hyperphagia in PWS, and the reauthorization process for claims has been overwhelmingly positive, with most patients quickly re-approved for continued therapy. This indicates that VICAT XR is not only gaining clinical adoption but is also being viewed as a cost-effective, value-driven therapy by payers—a critical determinant of long-term commercial success in rare diseases. Furthermore, the company’s Soleno One co-pay support program effectively mitigates seasonal gross-to-net pressures, as noted by the CFO, ensuring stable net pricing despite commercial plan resets. The low discontinuation rate related to adverse events (approximately 12% launch-to-date) and high real-world adherence suggest patients are experiencing meaningful benefit, which supports both persistence and willingness to pay. As the drug moves beyond early adopters into broader community use, the combination of strong efficacy signals, manageable side effects, and payer validation could enable Soleno to maintain or even increase net prices over time, particularly if competing therapies remain absent. This pricing stability, coupled with operating leverage from scalable SG&A and declining R&D spend as a percentage of revenue, points to margin expansion potential that may not be fully reflected in current valuations.

Soleno Therapeutics, Inc. is positioned for significant upside from the near-term approval and commercial launch of VICAT XR in the European Union, an opportunity management highlighted but did not fully quantify in terms of near-term revenue impact. The company has already navigated the Day 120 questions from the EMA and is anticipating Day 180 questions imminently, with a decision expected in mid-year 2026. Given the concentrated nature of the PWS patient population in Europe—estimated at 9,500 individuals under E4—and the strong presence of centers of excellence and thought leader support, the path to adoption could mirror or exceed the U.S. launch trajectory. Management noted they are building their own commercial team on the ground, indicating confidence in a standalone launch capability, which would preserve full economic value. The U.S. launch achieved approximately 12.5% penetration of the addressable market in under nine months, translating to 859 active patients by year-end 2025. Applying a similar adoption rate in the EU could yield over 1,100 patients within the first year post-approval, generating substantial incremental revenue at current U.S. pricing levels. This expansion represents a structural growth catalyst that the market may be underestimating, particularly as the company transitions from a single-geography to a dual-commercial entity, derisking its revenue base and enhancing long-term scalability.
The ongoing development of VICAT XR for glycogen storage disease type 1 (GSD1) presents a high-probability, low-cost pipeline catalyst that could significantly extend the drug’s commercial lifespan and address a clear unmet need with minimal commercial overlap. Management explicitly identified GSD1 as a natural extension of the VICAT XR franchise, noting the shared physician base (pediatric endocrinologists), the mechanism of action’s direct applicability to hypoglycemia prevention, and the orphan designation already secured in both the U.S. and EU. The company plans to file an IND in 2026, leveraging existing knowledge of the drug’s pharmacology and safety profile. Unlike de novo drug development, this indication benefits from prior clinical exposure, reducing both development risk and time-to-trial initiation. With approximately 3,000–4,000 patients in the U.S. and a similar prevalence globally, GSD1 represents a meaningful secondary market that could be commercialized with a lean, focused effort—potentially through the same specialty pharmacy and field infrastructure already in place for PWS. The lack of existing FDA-approved therapies and the life-threatening nature of untreated GSD1 create strong pricing and reimbursement potential, while the drug’s ability to reduce dependence on frequent cornstarch dosing offers a compelling quality-of-life benefit that could drive rapid adoption among neurologists and metabolic specialists. This pipeline expansion is not being promoted as a near-term revenue driver but could become a material contributor to growth by 2028–2029, offering optionality that the market is not currently pricing in.
Soleno Therapeutics, Inc. exhibits signs of durable pricing power and reimbursement resilience that could support margin expansion and sustained revenue growth beyond initial launch dynamics, a factor that received limited emphasis during the earnings call despite strong underlying evidence. The company reported broad commercial, Medicaid, and Medicare coverage policies covering over 180 million lives by the end of 2025, including strong reimbursement from approximately 45 state Medicaid programs. Payers are recognizing the serious unmet need in treating hyperphagia in PWS, and the reauthorization process for claims has been overwhelmingly positive, with most patients quickly re-approved for continued therapy. This indicates that VICAT XR is not only gaining clinical adoption but is also being viewed as a cost-effective, value-driven therapy by payers—a critical determinant of long-term commercial success in rare diseases. Furthermore, the company’s Soleno One co-pay support program effectively mitigates seasonal gross-to-net pressures, as noted by the CFO, ensuring stable net pricing despite commercial plan resets. The low discontinuation rate related to adverse events (approximately 12% launch-to-date) and high real-world adherence suggest patients are experiencing meaningful benefit, which supports both persistence and willingness to pay. As the drug moves beyond early adopters into broader community use, the combination of strong efficacy signals, manageable side effects, and payer validation could enable Soleno to maintain or even increase net prices over time, particularly if competing therapies remain absent. This pricing stability, coupled with operating leverage from scalable SG&A and declining R&D spend as a percentage of revenue, points to margin expansion potential that may not be fully reflected in current valuations.

▼ Bear case

Soleno Therapeutics, Inc. faces significant near-term growth deceleration risks in the U.S. market that management acknowledged only implicitly, particularly as the initial wave of eager adopters is exhausted and the company confronts the harder-to-reach segments of the Prader-Willi syndrome population. While the company highlighted 1,250 patient start forms and 859 active patients by the end of 2025—representing approximately 12.5% of the addressable market—the cadence of new starts has begun to slow, with only 207 start forms in Q4 2025 compared to higher quarterly rates earlier in the launch. Management framed the goal of 1,000 additional start forms over the next nine to twelve months as a continuation of momentum, but this implies a deceleration from the initial launch pace, which averaged nearly 140 start forms per month in the first six months post-approval. The increasing focus on caregiver outreach, community events, and KOL engagement—while necessary for broader adoption—suggests diminishing returns from early adopter channels and a need for more resource-intensive conversion efforts. Furthermore, the acknowledged lag between start forms and active patients due to benefits assessment (30–40 days) means that reported start form growth may overstate near-term revenue conversion. As the company shifts from innovator prescribers to community-based physicians, who may require more education and face higher procedural barriers, the cost per acquisition is likely to rise, potentially slowing active patient growth and pressuring revenue growth rates in 2026, a dynamic not fully priced into current expectations.
The European Union regulatory pathway for VICAT XR remains uncertain and could face delays or rejection despite management’s optimism, a risk underscored by the nature of the EMA’s Day 120 questions and historical precedents in rare disease approvals. Management acknowledged that the key concerns from the EMA centered on the adequacy of the data to prove efficacy, particularly regarding the randomized withdrawal study design and potential bias from using the same patients in both early and late phases of the trial—criticisms that mirror those raised during the FDA review process. While the company prevailed with the FDA, the EMA has historically been more conservative in its assessment of withdrawn study designs, especially in neurobehavioral endpoints, and has shown less tolerance for open-label extensions or limited control groups. The company’s reliance on a single pivotal trial for approval increases regulatory risk, and the absence of a dedicated safety or efficacy trial specifically for the EU population introduces uncertainty about generalizability. Furthermore, the recent negative vote on trofinetide in the EU, despite its FDA approval, illustrates that regulatory divergence between the U.S. and Europe is not uncommon in rare disease neurology, and Soleno cannot assume that FDA approval guarantees EMA endorsement. A delay beyond mid-year 2026 or a complete rejection would not only defer expected EU revenue but could also signal broader concerns about the trial’s robustness, potentially impacting investor confidence and complicating future pipeline efforts like GSD1.
Soleno Therapeutics, Inc. is exposed to underestimated margin pressure from rising cost of goods sold and increasing operational complexity as the zero-cost inventory is depleted and commercial scale-up demands greater investment, a trend that was downplayed during the earnings call despite clear forward-looking signals. The CFO explicitly noted that cost of goods sold, which benefited from expensed pre-approval inventory, will “gently nudge up” as full-cost inventory flows through the supply chain, with expectations of settling in the mid-single digits as a percentage of revenue. While this may seem modest, the transition from near-zero COGS to even 4–5% represents a doubling or tripling of the cost base, directly impacting gross margin at a time when SG&A expenses are already expanding to support commercialization efforts. Full-year SG&A rose to $132.1 million in 2025 from $115.9 million in 2024, driven by investments in personnel and programs to support the VICAT XR launch, and this trend is likely to continue as the company expands its field force for EU readiness and GSD1 planning. Concurrently, R&D expenses, while down year-over-year, are expected to increase again as IND-enabling work for GSD1 begins in 2026. The combination of rising COGS, sustained or growing SG&A, and potential R&D reaccumulation could compress operating margins faster than anticipated, particularly if U.S. revenue growth decelerates and EU revenue remains delayed or uncertain. This margin vulnerability is not being highlighted as a near-term concern but could become a meaningful headwind to profitability in 2026–2027, challenging the perception of the company as a rapidly scaling, high-margin commercial entity.

Soleno Therapeutics, Inc. faces significant near-term growth deceleration risks in the U.S. market that management acknowledged only implicitly, particularly as the initial wave of eager adopters is exhausted and the company confronts the harder-to-reach segments of the Prader-Willi syndrome population. While the company highlighted 1,250 patient start forms and 859 active patients by the end of 2025—representing approximately 12.5% of the addressable market—the cadence of new starts has begun to slow, with only 207 start forms in Q4 2025 compared to higher quarterly rates earlier in the launch. Management framed the goal of 1,000 additional start forms over the next nine to twelve months as a continuation of momentum, but this implies a deceleration from the initial launch pace, which averaged nearly 140 start forms per month in the first six months post-approval. The increasing focus on caregiver outreach, community events, and KOL engagement—while necessary for broader adoption—suggests diminishing returns from early adopter channels and a need for more resource-intensive conversion efforts. Furthermore, the acknowledged lag between start forms and active patients due to benefits assessment (30–40 days) means that reported start form growth may overstate near-term revenue conversion. As the company shifts from innovator prescribers to community-based physicians, who may require more education and face higher procedural barriers, the cost per acquisition is likely to rise, potentially slowing active patient growth and pressuring revenue growth rates in 2026, a dynamic not fully priced into current expectations.
The European Union regulatory pathway for VICAT XR remains uncertain and could face delays or rejection despite management’s optimism, a risk underscored by the nature of the EMA’s Day 120 questions and historical precedents in rare disease approvals. Management acknowledged that the key concerns from the EMA centered on the adequacy of the data to prove efficacy, particularly regarding the randomized withdrawal study design and potential bias from using the same patients in both early and late phases of the trial—criticisms that mirror those raised during the FDA review process. While the company prevailed with the FDA, the EMA has historically been more conservative in its assessment of withdrawn study designs, especially in neurobehavioral endpoints, and has shown less tolerance for open-label extensions or limited control groups. The company’s reliance on a single pivotal trial for approval increases regulatory risk, and the absence of a dedicated safety or efficacy trial specifically for the EU population introduces uncertainty about generalizability. Furthermore, the recent negative vote on trofinetide in the EU, despite its FDA approval, illustrates that regulatory divergence between the U.S. and Europe is not uncommon in rare disease neurology, and Soleno cannot assume that FDA approval guarantees EMA endorsement. A delay beyond mid-year 2026 or a complete rejection would not only defer expected EU revenue but could also signal broader concerns about the trial’s robustness, potentially impacting investor confidence and complicating future pipeline efforts like GSD1.
Soleno Therapeutics, Inc. is exposed to underestimated margin pressure from rising cost of goods sold and increasing operational complexity as the zero-cost inventory is depleted and commercial scale-up demands greater investment, a trend that was downplayed during the earnings call despite clear forward-looking signals. The CFO explicitly noted that cost of goods sold, which benefited from expensed pre-approval inventory, will “gently nudge up” as full-cost inventory flows through the supply chain, with expectations of settling in the mid-single digits as a percentage of revenue. While this may seem modest, the transition from near-zero COGS to even 4–5% represents a doubling or tripling of the cost base, directly impacting gross margin at a time when SG&A expenses are already expanding to support commercialization efforts. Full-year SG&A rose to $132.1 million in 2025 from $115.9 million in 2024, driven by investments in personnel and programs to support the VICAT XR launch, and this trend is likely to continue as the company expands its field force for EU readiness and GSD1 planning. Concurrently, R&D expenses, while down year-over-year, are expected to increase again as IND-enabling work for GSD1 begins in 2026. The combination of rising COGS, sustained or growing SG&A, and potential R&D reaccumulation could compress operating margins faster than anticipated, particularly if U.S. revenue growth decelerates and EU revenue remains delayed or uncertain. This margin vulnerability is not being highlighted as a near-term concern but could become a meaningful headwind to profitability in 2026–2027, challenging the perception of the company as a rapidly scaling, high-margin commercial entity.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password